Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
December 19th, 2020
Genetic code expansion is applied for the introduction of an unnatural amino acid bearing a biorthogonal functional group on a carrier protein at a defined site. The biorthogonal function is further used for the site-selective coupling of a carbohydrate antigen to provide a homogeneous glycoconjugate vaccine.
Overview
This study focuses on the production of a homogeneous glycoconjugate vaccine through the incorporation of an unnatural amino acid and click-chemistry. The methodology involves genetic code expansion to introduce a biorthogonal functional group on a carrier protein, facilitating the site-selective coupling of a carbohydrate antigen.
Key Study Components
Area of Science
- Biochemistry
- Immunology
- Protein Engineering
Background
- Genetic code expansion allows for the incorporation of unnatural amino acids into proteins.
- This technique can modify protein characteristics and create new functions.
- Codon suppression is a popular method for unnatural amino acid incorporation.
- Homogeneous glycoconjugate vaccines are important for targeted immunotherapy.
Purpose of Study
- To produce a glycoconjugate vaccine using non-canonical amino acid incorporation.
- To utilize click-chemistry for efficient oligosaccharide coupling.
- To demonstrate the application of genetic code expansion in vaccine development.
Methods Used
- Genetic code expansion for unnatural amino acid incorporation.
- Codon suppression method for site-specific amino acid addition.
- Synthesis of propargyl-lysine from Boc-lysine.
- Click-chemistry for site-selective coupling of carbohydrate antigens.
Main Results
- Successful incorporation of an unnatural amino acid with a biorthogonal functional group.
- Efficient grafting of synthetic oligosaccharide hapten onto the carrier protein.
- Production of a homogeneous glycoconjugate vaccine demonstrated.
- Methodology shows potential for future vaccine development.
Conclusions
- The study confirms the feasibility of using genetic code expansion in vaccine production.
- Click-chemistry provides a robust approach for creating glycoconjugates.
- This methodology could advance the development of targeted immunotherapies.
Frequently Asked Questions
Executive Industry Relevance
Homogeneous glycoconjugate vaccines are critical for meeting stringent regulatory requirements for physico-chemical characterization and ensuring reproducible immunogenicity. This method enables precise structure-function studies by providing a defined 1:1 hapten-to-protein ratio, supporting rational vaccine design and de-risking of preclinical candidates. The approach addresses a key gap in vaccine development by overcoming heterogeneity inherent in classical conjugation strategies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of structure-immunogenicity relationships through precise glycan positioning on carrier proteins.
- Operational Value: Provides a defined molecular entity for hypothesis testing in target validation workflows.
Screening & Assay Development
- Scientific Value: Generates homogeneous antigens for reproducible immunoassay development and antibody screening.
- Operational Value: Ensures batch-to-batch consistency in antigen presentation, reducing variability in functional readouts.
Translational & Preclinical Research
- Scientific Value: Supports mechanistic de-risking by linking defined glycan structures to immune responses in disease-relevant models.
- Operational Value: Enables scalable production of defined conjugates for toxicology and efficacy studies.
Pipeline & Workflow Integration
The method integrates into early discovery through lead identification, providing a platform for generating defined immunogens prior to preclinical evaluation.
- Discovery Biology: Supports hypothesis testing via site-specific antigen presentation to clarify immune target engagement.
- Screening: Delivers quantitative, homogeneous antigens for standardized binding and neutralization assays.
- Analytics: Enables precise mass spectrometry and SDS-PAGE characterization to confirm conjugation efficiency and homogeneity.
- Translational Research: Facilitates continuity from discovery to preclinical by providing structurally defined vaccines for immunogenicity testing.
- Enterprise Reuse: Establishes a reusable platform for generating diverse glycoconjugates using orthogonal click-chemistry pairs.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence through reduced mechanistic ambiguity in antigen-antibody interactions.
- Operational Value: Standardization and reproducibility via site-specific conjugation eliminating batch heterogeneity.
- Strategic Value: Improved go/no-go decisions by enabling structure-based immunogenicity predictions.
- Portfolio Impact: Risk-adjusted prioritization through defined structure-activity relationships in vaccine candidates.
Implementation Considerations
- Expertise in genetic code expansion, click-chemistry, and protein purification.
- Instrumentation for NMR, mass spectrometry, and fluorescence detection.
- Standardization of conjugation conditions across teams and sites.
- Adaptation to different carrier proteins and hapten structures.
- Limitations include 1:1 conjugation stoichiometry and dependence on efficient UAA incorporation.
Biopharma FAQs
Chapters in this video
0:00
Introduction
0:54
Synthesis of the UAA: Propargyl-L-Lysine (Prk)
4:46
Production of the Recombinant Protein modified by PrK
8:13
Removal of the Histidine Tag by TEV Protease Digestion
9:48
Assessment of PrK Accessibility and Functionality and Conjugation to the Hapten
11:26
Results: Efficient Incorporation of the PrK and Click Conjugation
12:49
Conclusion
